SITE006-0105

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE006 (GBR) · Dr. Rossi
consented 2022-07-06

AEs

Serious

Dropout signal

–

Adverse events

severe assessed

Grade 3 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-02 (study day 18); relationship: Y

severe assessed

Grade 3 Pneumonitis — outcome: RECOVERED/RESOLVED; onset 2022-11-01 (study day 109); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 170); relationship: N

severe serious assessed

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2024-06-05 (study day 691); relationship: N; serious criteria: hospitalization

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2024-11-03 (study day 842); relationship: not assessed

Data queries

No data queries.